CBX-12
Platinum-resistant or refractory ovarian cancer
Key Facts
About Cybrexa Therapeutics
Cybrexa Therapeutics is a private, clinical-stage biotech pioneering an antigen-agnostic approach to targeted cancer therapy via its alphalex™ peptide-drug conjugate platform. The platform exploits the acidic tumor microenvironment to selectively deliver highly potent cytotoxic payloads directly into tumor cells, aiming to overcome limitations of antibody-drug conjugates (ADCs) like antigen dependency and associated toxicities. The company's lead asset, CBX-12, is in Phase 2 for platinum-resistant ovarian cancer, with a broader pipeline in preclinical development. Cybrexa represents a compelling player in the next wave of targeted oncology therapeutics, with the potential to address a wide range of solid tumors.
View full company profile